Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · InMed Pharmaceuticals Inc. (INM)

InMed completes 1-for-10 share consolidation and name change to Mentari Therapeutics

Neutral Impact 4 of 5 m&a Written later

InMed Pharmaceuticals completed a 1-for-10 consolidation of its common shares and legally changed its name to Mentari Therapeutics, Inc., effective November 4, 2026, after shareholders approved all items at its annual general and special meeting. Shareholders approved the Nasdaq Share Issuance Proposal tied to the pending merger with Mentari, and the share count falls from about 5,493,735 to about 549,374, with trading under INM expected to resume on a post-consolidation basis on November 5, 2026.

Key points

  • Shareholders approved the Nasdaq Share Issuance Proposal with 97.295% of votes cast in favor (2,615,030 shares), covering shares to be issued in the merger with Mentari Therapeutics.
  • Consolidation: one post-consolidation common share for each ten pre-consolidation shares, reducing shares outstanding from 5,493,735 to about 549,374.
  • Common shares expected to trade on The Nasdaq Capital Market under INM from the start of trading on November 5, 2026, with new CUSIP 457637809.
  • One contingent value right per share is expected to be issued to holders of record at the close of business on November 5, 2026, under a CVR agreement to be entered into by the merger closing date.

The filing

CompanyInMed Pharmaceuticals Inc. (INM)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:08 AM ET
Accession number0001062993-26-005760

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.